Geisinger turns to sequencing
Geisinger is expanding its population health genomics program beyond research and into routine clinical practice, effectively enabling the healthcare organization’s patients to be the first in the nation to have the sequencing of their DNA as part of standard care. “Understanding the genome warning signals of every patient will be an essential part of wellness planning and health management,” said David Feinberg, MD, president and CEO of Geisinger. “Geisinger patients will be able to work with their family physician to modify their lifestyle and minimize risks that may be revealed. This forecasting will allow us to provide truly anticipatory healthcare.” According to Feinberg, Geisinger will launch its clinical DNA sequencing initiative with a 1,000-patient pilot program over the next six months. Once the pilot is completed, the program will then be rolled out throughout its
sites in Pennsylvania and southern New Jersey. Geisinger’s MyCode Community Health Initiative—a precision medicine research effort launched in 2007 by the Danville, Penn.-based health system—will serve as the model for integrating genomics and data science into everyday preventive care at the provider organization. The MyCode Community Health Initiative, which has enrolled more than 200,000 participants, has identified more than 500 patients who are at increased risk and has uncovered previously undetected cases of cancer and heart disease, enabling its physicians to treat them much earlier than they could have otherwise. Geisinger has partnered with Regeneron Genetics Center, a biopharmaceutical company in Tarrytown, N.Y., to generate clinical reports with testing results. that are put into the EHR and provided to patients, who are then offered genetic counseling.